胰腺腺癌:计算机断层扫描、磁共振成像与病理标本测量肿瘤大小的变异性
本研究纳入114例经组织学确诊的胰腺导管腺癌(PDAC)患者,术前均行增强CT和MRI检查,比较CT、MRI与手术病理标本测量的肿瘤大小。Bland-Altman分析显示CT和MRI较病理分别低估肿瘤平均大小4.3 mm和5.8 mm,肿瘤>30 mm时影像测量更偏小,且不同T分期间差异显著(P<0.001)。
要点
- 增强CT和MRI测量的PDAC肿瘤大小均小于病理标本,平均低估分别为4.3 mm和5.8 mm。
- 肿瘤>30 mm时,CT或MRI测量的肿瘤大小较病理偏小。
- 不同T分期肿瘤的影像与病理大小差异显著不同(P<0.001)。
核心结论
- 与病理标本相比,增强CT和MRI分别将PDAC肿瘤平均大小低估4.3 mm和5.8 mm。
- 肿瘤越大,CT/MRI与病理标本之间PDAC大小测量的差异越大。
研究设计与样本
- 研究纳入114例经组织学确诊的PDAC患者,术前均接受增强CT和MRI检查,并与手术切除病理标本测量结果比较。
- 采用Bland-Altman分析和组内相关系数(ICC)比较CT、MRI与病理标本的肿瘤大小。
- 采用Pearson相关系数和多因素线性回归分析肿瘤位置(胰头/颈、体或尾)、T分期(T1、T2或T3)和N分期(N0、N1或N2)等差异影响因素。
诊断标准与关键数值
- CT与病理标本测量的肿瘤大小平均差异为4.3 mm(ICC 0.67),MRI与病理标本平均差异为5.8 mm(ICC 0.65)。
- CT与病理标本测量的一致性界限(LOA)为-28.9至21.4,MRI与病理标本的LOA为-29.4至17.8。
- 三种测量方法的平均肿瘤大小之间差异有统计学意义(P<0.001)。
- 不同T分期肿瘤的CT/MRI与病理标本大小差异有统计学意义(P<0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To compare the tumor size measurements assessed by computed tomography (CT) and magnetic resonance imaging (MRI) versus measurements of resected pathologic specimens from patients with pancreatic ductal adenocarcinoma (PDAC).
METHODS: This study included 114 patients with histologically confirmed PDAC who underwent contrast-enhanced CT and MRI before surgery. The tumor sizes from CT, MRI, and pathologic specimens were compared by using Bland-Altman analyses and intraclass correlation coefficients (ICCs). The discrepancies in PDAC size between CT/MRI and pathologic specimens were calculated and contributing factors for the discrepancies, including tumor locations (pancreatic head/neck, body, or tail), T stages (T1, T2, or T3), and N stages (N0, N1, or N2), were analyzed with Pearson's correlation coefficients and multivariable linear regression analyses.
RESULTS: There was significant difference among the mean tumor sizes of three measurements (P < 0.001). The difference in mean tumor size between the pathologic sizes for PDAC was 4.3 mm (ICC 0.67) on CT and 5.8 mm (ICC 0.65) on MRI. Both CT and MRI showed wide ranges of limits of agreement (LOAs) between the pathologic specimens for tumor size measurements (LOAs, - 28.9 to 21.4 and - 29.4 to 17.8, respectively). The tumor size on CT or MRI was estimated to be smaller than that on pathology when the tumor was > 30 mm. The discrepancies in the tumor size estimated between CT/MRI and pathologic specimens were significantly different for tumors of different T stages (P < 0.001).
CONCLUSIONS: Both contrast-enhanced CT and MRI underestimate the mean tumor size by 4.3 mm and 5.8 mm, respectively, compared to the size of pathologic specimens. A larger tumor size indicates a greater discrepancy in the PDAC size measurements between CT/MRI and pathologic specimens.
引用
- Ma C, Yang P, Li J, et al. Pancreatic adenocarcinoma: variability in measurements of tumor size among computed tomography, magnetic resonance imaging, and pathologic specimens. Abdom Radiol (NY). 2020. PMID: 31292672. doi:10.1007/s00261-019-02125-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。